Danny Rimer, partner at Index Ventures, led Figma’s seed round in 2013, when the company’s stock was valued at just 9 cents ...

Will Griffith is a seed investor in Figma. Investors didn't want to sell millions of shares. He explains why they did it ...

VC firm Frazier Life Sciences has raised a $1.3 billion fund, the firm’s largest to date and one of the few new biotech ...

US-based cyber-risk management Safe Security or SAFE, which counts venture-capital firms such as Sorenson Capital and ...

The second quarter of 2025 funding data tells a story of capital concentration, sector rotation and investor discipline. Read more here.

Frazier was among the most active venture investors in 2024, according to analysts at William Blair, backing 17 private life ...

Figma rallied 250 per cent to $115.50 a share on Thursday as it started trading on the New York Stock Exchange following an ...

Named after legendary investment banker Tony James, the Centre aims to be a global thought leader for research in all matters ...

A new wave of value-retail startups like SuperK, Apna Mart, and Aap ka Bazar is drawing strong venture capital interest by ...

Rehan Yar Khan, Managing Partner at Orios Venture Partners, shares why disciplined contrarian bets on pivoting startups ...

Investors are deploying less capital in biotech startups as a cloudy market outlook and a dearth of IPOs hobble the sector.

The venture market recovery isn't a recovery at all, according to guest author Steve Brotman, who writes that what we're ...